Ohara Yasuhiro, Matsubayashi Hidehiko, Suzuki Yosuke, Takaya Yukiko, Yamaguchi Kohei, Doshida Masakazu, Takeuchi Takumi, Ishikawa Tomomoto, Handa Mika, Miyake Tatsuya, Takiuchi Tsuyoshi, Kimura Tadashi
Department of Reproductive Medicine Reproduction Clinic Tokyo Tokyo Japan.
Department of Obstetrics and Gynecology Graduate School of Medicine Osaka University Suita Japan.
Reprod Med Biol. 2022 Feb 7;21(1):e12444. doi: 10.1002/rmb2.12444. eCollection 2022 Jan-Dec.
To assess the clinical efficacy of personalized embryo transfer (pET) guided by a new endometrial receptivity test, ERPeak, in patients with recurrent implantation failure (RIF).
Recurrent implantation failure patients of all ages at two private Japanese clinics from April 2019 to June 2020 were retrospectively analyzed. The intervention group ( = 244) received pET in accordance with endometrial receptivity testing results and was compared to control group ( = 306) receiving standardized timing, non-personalized embryo transfer (npET). In propensity score matching analysis, the clinical pregnancy rate (CPR) and live birth rate (LBR) were compared between groups, and a subanalysis of advanced maternal age (AMA) (≥38 years old) versus non-AMA (<38 years old) patients was also conducted.
The CPR and LBR of the pET group were significantly higher than those of the npET group (37.7% vs. 20.0%, adjusted OR: 2.64; 95%CI, 1.70-4.11, < 0.001 and 29.9% vs. 9.7%, adjusted OR: 4.13; 95%CI, 2.40-7.13, < 0.001, respectively). Furthermore, in the subanalyses, the CPR and LBR of the pET group were significantly higher than those of the npET group in both the AMA non-AMA patients.
The new ERPeak endometrial receptivity test is a useful alternative diagnostic tool for poor-prognosis patients, regardless of age.
评估一种新型子宫内膜容受性检测方法ERPeak指导下的个性化胚胎移植（pET）在反复种植失败（RIF）患者中的临床疗效。
回顾性分析2019年4月至2020年6月在两家日本私立诊所就诊的各年龄段反复种植失败患者。干预组（n = 244）根据子宫内膜容受性检测结果接受pET，并与接受标准化时间、非个性化胚胎移植（npET）的对照组（n = 306）进行比较。在倾向评分匹配分析中，比较两组之间的临床妊娠率（CPR）和活产率（LBR），并对高龄产妇（AMA）（≥38岁）与非AMA（<38岁）患者进行亚分析。
pET组的CPR和LBR显著高于npET组（分别为37.7%对20.0%，调整后的OR：2.64；95%CI，1.70 - 4.11，P < 0.001和29.9%对9.7%，调整后的OR：4.13；95%CI，2.40 - 7.13，P < 0.001）。此外，在亚分析中，pET组的CPR和LBR在AMA和非AMA患者中均显著高于npET组。
新型ERPeak子宫内膜容受性检测对于预后不良的患者是一种有用的替代诊断工具，无论年龄大小。
